Suplatast tosilate

Suplatast tosilate (INN) is a Th2 cytokine inhibitor that can correct the imbalance in the Th1/Th2 immune response and shows clear clinical efficacy in bronchial asthma (BA).

The drug has been successfully used a few times to treat Kimura disease (Tamaoki J et al. 2000; Ueda Tet al. 2011).

Suplatast tosilate is able to suppress the production of IgE, block the production of cytokines, and suppress allergy-related eosinophils.

Clinical studies on the efficacy of Suplatast have been conducted in Japan. Suplatast showed reasonable efficacy in the treatment of bronchial asthma, allergic rhinitis, and atopic dermatitis.

Suplatast tosilate is not approved in the U.S. but is available in Japan as Tosilart® and IPD Capsules®.

1. Butterfield JH (2021) Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone. J Investig Med High Impact Case Rep 2324709620987691.
2. Tamaoki J et al (2000) Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group. Lancet. 356: 273-278.
3. Tsukagoshi H et al. (1998) Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate. Internal Medicine 37: 1064-1067.
4. Ueda Tet al. (2011) Kimura's disease treated with suplatast tosilate and loratadine. European Journal of Dermatology 21: 1020-1021.